Technical Analysis for CLIGF - Clinigen Group Plc

Grade Last Price % Change Price Change
grade B 10.21 4.18% 0.4100
CLIGF closed up 4.18 percent on Tuesday, June 23, 2020, on 34 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical CLIGF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish 4.18%
Narrow Range Bar Range Contraction 4.18%
Wide Bands Range Expansion 4.18%
Overbought Stochastic Strength 4.18%
Gapped Down Weakness 4.18%
Narrow Range Bar Range Contraction -4.97%
Older signals for CLIGF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Medicine Health Pharmaceutical Industry Medication Radiation Chemotherapy Clinical Trial Pharmacist Radiation Treatment Anthracycline Cardioxane Comparator Medicines And Services Dexrazoxane Diketopiperazines Extravasation Imides

Is CLIGF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 12.5921
52 Week Low 6.0
Average Volume 1,189
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 8.3869
10-Day Moving Average 9.2543
Average True Range 0.7106
ADX 20.93
+DI 48.9546
-DI 49.6592
Chandelier Exit (Long, 3 ATRs ) 10.1682
Chandelier Exit (Short, 3 ATRs ) 8.1318
Upper Bollinger Band 11.5473
Lower Bollinger Band 5.2265
Percent B (%b) 0.79
BandWidth 75.3652
MACD Line 0.1059
MACD Signal Line -0.2883
MACD Histogram 0.3942
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.2100
Resistance 3 (R3) 10.2100 10.2100 10.2100
Resistance 2 (R2) 10.2100 10.2100 10.2100 10.2100
Resistance 1 (R1) 10.2100 10.2100 10.2100 10.2100 10.2100
Pivot Point 10.2100 10.2100 10.2100 10.2100 10.2100
Support 1 (S1) 10.2100 10.2100 10.2100 10.2100 10.2100
Support 2 (S2) 10.2100 10.2100 10.2100 10.2100
Support 3 (S3) 10.2100 10.2100 10.2100
Support 4 (S4) 10.2100